Inventor · disambiguated record
Sha Mi
Also filed as: MI SHA
34 granted patents·36 pending applications·534 citations·filing 1996–2021
98Inventor score
Top patents by PatentIndex Score
70 records- 0197US8425910B2Composition comprising antibodies to LINGO or fragments thereofMI SHA·Filed 2011·Granted Apr 23, 2013·44 cites·11 claims
- 0297US8058406B2Composition comprising antibodies to LINGO or fragments thereofMI SHA·Filed 2009·Granted Nov 15, 2011·48 cites·15 claims
- 0396US8128926B2Sp35 antibodies and uses thereofMI SHA·Filed 2009·Granted Mar 6, 2012·29 cites·20 claims
- 0495US9066984B2Sp35 antibodies and uses thereofBIOGEN IDEC INC·Filed 2013·Granted Jun 30, 2015·26 cites·6 claims
- 0595US8551476B2SP35 antibodies and uses thereofMI SHA·Filed 2007·Granted Oct 8, 2013·34 cites·16 claims
- 0693US8153580B2Nogo receptor binding proteinMI SHA·Filed 2010·Granted Apr 10, 2012·17 cites·16 claims
- 0793US6043344AHuman CTLA-8 and uses of CTLA-8-related proteinsGENETICS INST·Filed 1998·Granted Mar 28, 2000·129 cites·13 claims
- 0891US6902735B1Antibodies to human IL-17F and other CTLA-8-related proteinsINST GENETICS LLC·Filed 2002·Granted Jun 7, 2005·30 cites·30 claims
- 0990US8894999B2Use of DR6 and p75 antagonists to promote survival of cells of the nervous systemBIOGEN IDEC INC·Filed 2013·Granted Nov 25, 2014·10 cites·14 claims
- 1090US8609407B2Sp35 antibodies and uses thereofMI SHA·Filed 2012·Granted Dec 17, 2013·6 cites·18 claims
- 1187US8501178B2Use of DR6 and p75 antagonists to promote survival of cells of the nervous systemMI SHA·Filed 2009·Granted Aug 6, 2013·7 cites·18 claims
- 1287US7846438B2Methods of promoting neurite outgrowth with soluble TAJ polypeptidesBIOGEN IDEC INC·Filed 2005·Granted Dec 7, 2010·8 cites·16 claims
- 1386US9550798B2Compounds that are S1P modulating agents and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Jan 24, 2017·8 cites·25 claims
- 1486US8765662B2NOGO receptor binding proteinMI SHA·Filed 2012·Granted Jul 1, 2014·6 cites·16 claims
- 1586US8642040B2Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonistsMI SHA·Filed 2007·Granted Feb 4, 2014·24 cites·10 claims
- 1686US8486893B2Treatment of conditions involving demyelinationMI SHA·Filed 2005·Granted Jul 16, 2013·8 cites·20 claims
- 1785US9555050B2ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Jan 31, 2017·4 cites·24 claims
- 1885US7785829B2Nogo receptor binding proteinBIOGEN IDEC INC·Filed 2004·Granted Aug 31, 2010·15 cites·29 claims
- 1984US9340527B2S1P modulating agentsTHOMAS JERMAINE·Filed 2012·Granted May 17, 2016·6 cites·38 claims
- 2083US9107884B2Use of semaphorin 6A for promoting myelination and oligodendrocyte differentiationCHEDOTAL ALAIN·Filed 2008·Granted Aug 18, 2015·16 cites·14 claims
- 2182US9522889B2ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Dec 20, 2016·5 cites·31 claims
- 2281US10034869B2S1P modulating agentsBIOGEN MA INC·Filed 2017·Granted Jul 31, 2018·2 cites·18 claims
- 2381US8932821B2NOGO receptor binding proteinBIOGEN IDEC INC·Filed 2013·Granted Jan 13, 2015·3 cites·4 claims
- 2480US9808449B2S1P modulating agentsBIOGEN MA INC·Filed 2015·Granted Nov 7, 2017·2 cites·21 claims
- 2576US10894040B2S1P modulating agentsBIOGEN MA INC·Filed 2019·Granted Jan 19, 2021·0 cites·20 claims
- 2676US9745375B2Compositions comprising antibodies to LINGO or fragments thereofBIOGEN MA INC·Filed 2016·Granted Aug 29, 2017·1 cites·21 claims
- 2775US2021395360A1SP35 Antibodies And Uses ThereofBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 2874US6074849APolynucleotides encoding human CTLA-8 related proteinsGENETICS INST·Filed 1996·Granted Jun 13, 2000·34 cites·10 claims
- 2973US9796780B2LINGO-2 antagonists for treatment of conditions involving motor neuronsBIOGEN MA INC·Filed 2013·Granted Oct 24, 2017·1 cites·9 claims
- 3071US9068992B2Screening methods for identifying Sp35 antagonistsBIOGEN IDEC INC·Filed 2013·Granted Jun 30, 2015·1 cites·20 claims
- 3171US2020317775A1SP35 Antibodies And Uses ThereofBIOGEN MA INC·Filed 2020·Application pending·0 cites
- 3269US2020297800A1Use of lingo-4 antagonists in the treatment of conditions involving demyelinationBIOGEN MA INC·Filed 2020·Application pending·0 cites
- 3367US2019161546A1SP35 Antibodies And Uses ThereofBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 3465US10406144B2SIP modulating agentsBIOGEN MA INC·Filed 2018·Granted Sep 10, 2019·0 cites·18 claims
- 3565US2021260185A1Combination Therapies and Uses for Treatment of Demyelinating DisordersBIOGEN MA INC·Filed 2020·Application pending·0 cites
- 3665US2013287796A1Sp35 Antibodies and Uses ThereofBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 3765US2011123553A1Use of LINGO-4 Antagonists in the Treatment of Conditions Involving DemyelinationBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 3864US2020276303A1Combination Therapies and Uses for Treatment of Demyelinating DisordersBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 3964US2015177240A1Nogo Receptor Binding ProteinBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
- 4062US2017037126A1SP35 Antibodies And Uses ThereofBIOGEN MA INC·Filed 2016·Application pending·0 cites
- 4162US2021277111A1Lingo-1 antagonists and uses for treatment of demyelinating disordersBIOGEN MA INC·Filed 2020·Application pending·0 cites
- 4261US2015315273A1SP35 Antibodies And Uses ThereofBIOGEN MA INC·Filed 2015·Application pending·0 cites
- 4361US2013323786A1Composition Comprising Antibodies to LINGO or Fragments ThereofBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 4460US2020216533A1Lingo-1 antagonists and uses for treatment of demyelinating disordersBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 4560US2019060398A1Use of lingo-4 antagonists in the treatment of conditions involving demyelinationBIOGEN MA INC·Filed 2018·Application pending·0 cites
- 4660US2009075884A1Human il-17f and other il-17f-related proteins and methods related theretoGENETICS INST LLC·Filed 2008·Application pending·0 cites
- 4760US2014199315A1Sp35 Antibodies and Uses ThereofBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 4859US2019359706A1Lingo-2 antagonists for treatment of conditions involving motor neuronsBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 4959US2010297121A1Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB AgonistsBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 5059US2015203585A1Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous SystemBIOGEN IDEC INC·Filed 2014·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Sha Mi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →